Cyril Mucha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cyril Mucha has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Lenka Hrdlickova
MSD Czech Republic, 150 00 Prague, Czech Republic
1 shared publication - Lenka Mokrá
Institut biostatistiky a analýz s.r.o, Brno, Czech Republic
1 shared publication - Matyáš Kuhn
Institute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic
1 shared publication - Pavel Dlouhý
Infectious Disease Department, Krajská Zdravotní, a.s., 400 11 Ústí nad Labem, Czech Republic
1 shared publication - Urs Arnet
MSD Innovation GmbH , CH-8058 Zurich Airport
1 shared publication - Yohance Omar Whiteside
Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ 07065, USA
1 shared publication
Latest Publications
- Open Access
- 16 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2303
Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20–99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.
- 16 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2303
Open AccessMolnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20–99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.